<DOC>
	<DOC>NCT02828644</DOC>
	<brief_summary>This is an exploratory study to assess potential maintenance of clinical benefit (cognition and symptoms) following 4 weeks of at-home digital therapy in ADHD children.</brief_summary>
	<brief_title>Software Treatment for Actively Reducing Severity of ADHD - Follow Up</brief_title>
	<detailed_description>The study will be a blinded (investigators and outcome assessors), randomized (from parent study Akili-001R), parallel group, follow-up study of the sustained effects of 4-weeks of treatment with either EVO Multitasking game-based digital therapy or EVO Words game-based digital therapy. The trial will consist of 4 visits: Screening (to be conducted at the same time as the end-of-study visit for the parent study Akili-001R), FU-Day 28 visit (conducted in clinic), and FU-Day 56 and FU-Day 84 visits (conducted remotely via electronically captured parent reported outcomes).</detailed_description>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>Completed Akili Study Akili001R including all clinical assessments at DAY28 per the study protocol Ability to comply with all the testing and requirements per this protocol Participant is currently considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or has a prior history of, or is currently demonstrating active suicidal ideation or selfinjurious behavior as measured by CSSRS at screening Participant has demonstrated clinically significant deterioration in functioning as assessed by PI and other study staff that would contraindicate continued participation in the followup study</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>ADHD</keyword>
</DOC>